Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune-mediated neuropathies.
This review deals with the use of intravenous IVIg immunoglobulins in the treatment of chronic immune-mediated neuropathies: multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, neuropathies associated with monoclonal gammopathies. A particular attention is given to case series and trials which compare IVIg to other therapies, such as steroid treatment immunosuppressors and plasma exchange. At present clinical and instrumental data seem to indicate the short term efficacy of IVIg in multifocal motor neuropathies, especially as early treatment; further studies are need in order to prove its long term efficacy in this disease. Concerning chronic inflammatory demyelinating polyneuropathies, short term IVIg efficacy is comparable to that of plasma exchange and in the long term most patients need repeated treatments. Most patients respond to the initial therapy and the initial nonresponders usually improve with a second treatment modality.
Comi
G
G
Department of Neurology, University of Milan, Scientific Institute H. San Raffaele, Italy.
Nemni
R
R
Amadio
S
S
Galardi
G
G
Leocani
L
L
D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D003711:Demyelinating Diseases / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation; D016472:Motor Neuron Disease / Q000276:immunology / Q000628:therapy*; D010265:Paraproteinemias / Q000276:immunology / Q000628:therapy; D010951:Plasma Exchange; D013256:Steroids / Q000627:therapeutic use
D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D013256:Steroids